Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of $177.74 million. The enterprise value is $139.68 million.
Important Dates
The last earnings date was Wednesday, September 17, 2025, before market open.
| Earnings Date | Sep 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 92.16 million shares outstanding. The number of shares has increased by 4.16% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 92.16M |
| Shares Change (YoY) | +4.16% |
| Shares Change (QoQ) | +7.02% |
| Owned by Insiders (%) | 0.98% |
| Owned by Institutions (%) | 1.90% |
| Float | 60.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.98 |
| Forward PS | 42.81 |
| PB Ratio | 29.42 |
| P/TBV Ratio | 29.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 5.25.
| Current Ratio | 2.21 |
| Quick Ratio | 2.08 |
| Debt / Equity | 5.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -102.40 |
Financial Efficiency
Return on equity (ROE) is -271.37% and return on invested capital (ROIC) is -65.68%.
| Return on Equity (ROE) | -271.37% |
| Return on Assets (ROA) | -25.92% |
| Return on Invested Capital (ROIC) | -65.68% |
| Return on Capital Employed (ROCE) | -79.81% |
| Revenue Per Employee | $81,987 |
| Profits Per Employee | -$298,797 |
| Employee Count | 181 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.20% in the last 52 weeks. The beta is 0.80, so Innate Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +8.20% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 44.05 |
| Average Volume (20 Days) | 24,220 |
Short Selling Information
| Short Interest | 53,076 |
| Short Previous Month | 48,691 |
| Short % of Shares Out | 0.07% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.63 |
Income Statement
In the last 12 months, Innate Pharma had revenue of $14.84 million and -$54.08 million in losses. Loss per share was -$0.64.
| Revenue | 14.84M |
| Gross Profit | -36.16M |
| Operating Income | -59.53M |
| Pretax Income | -54.08M |
| Net Income | -54.08M |
| EBITDA | -58.45M |
| EBIT | -59.53M |
| Loss Per Share | -$0.64 |
Full Income StatementBalance Sheet
The company has $70.50 million in cash and $31.74 million in debt, giving a net cash position of $38.75 million or $0.42 per share.
| Cash & Cash Equivalents | 70.50M |
| Total Debt | 31.74M |
| Net Cash | 38.75M |
| Net Cash Per Share | $0.42 |
| Equity (Book Value) | 6.04M |
| Book Value Per Share | 0.07 |
| Working Capital | 41.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$48.26 million and capital expenditures -$194,950, giving a free cash flow of -$47.86 million.
| Operating Cash Flow | -48.26M |
| Capital Expenditures | -194,950 |
| Free Cash Flow | -47.86M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
| Gross Margin | -243.65% |
| Operating Margin | -401.15% |
| Pretax Margin | -364.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.15% |
| Shareholder Yield | -4.15% |
| Earnings Yield | -30.43% |
| FCF Yield | -26.93% |
Analyst Forecast
The average price target for Innate Pharma is $5.00, which is 152.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | 152.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 58.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -6.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.27 |
| Piotroski F-Score | 2 |
